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but requires craniectomy. Application of endothelin-1, a 
potent vasoconstrictor, allows induction of transient focal 
ischemia in nearly any brain region and is frequently used 
to model lacunar stroke. Circumscribed and highly repro-
ducible cortical lesions are characteristic of photothrom-
botic stroke where infarcts are induced by photoactivation 
of a systemically given dye through the intact skull. The 
major shortcoming of this model is near complete lack of a 
penumbra. The two models mimicking human stroke most 
closely are various embolic stroke models and spontaneous 
stroke models. Closeness to reality has its price and goes 
along with higher variability of infarct size and location as 
well as unpredictable stroke onset in spontaneous models 
versus unpredictable reperfusion in embolic clot models.
Keywords Animal model · Cerebral ischemia · Focal 
ischemia · In vitro model · Non-human primate · Stroke
Introduction
On average every 40 s someone in the USA suffers a 
stroke, which drastically demonstrates the omnipresence 
and frequency of this devastating disease [92]. Acute cer-
ebral stroke is caused in the great majority of cases by 
occlusion of a supplying arterial vessel, whereas vessel 
rupture with associated hemorrhage accounts for a minor-
ity of about 15% [92]. The extent of the resulting brain 
injury after focal cerebral ischemia depends on many fac-
tors such as the severity and duration of ischemia or col-
lateral blood flow to mention the most important. This is in 
contrast to global cerebral ischemia, which mostly occurs 
in the setting of cardiac arrest, where—under normother-
mic conditions—relatively well-defined survival times of 
various neuronal subpopulations, glial and endothelial cells 
Abstract The vast majority of cerebral stroke cases are 
caused by transient or permanent occlusion of a cerebral 
blood vessel (“ischemic stroke”) eventually leading to 
brain infarction. The final infarct size and the neurologi-
cal outcome depend on a multitude of factors such as the 
duration and severity of ischemia, the existence of col-
lateral systems and an adequate systemic blood pressure, 
etiology and localization of the infarct, but also on age, 
sex, comorbidities with the respective multimedication 
and genetic background. Thus, ischemic stroke is a highly 
complex and heterogeneous disorder. It is immediately 
obvious that experimental models of stroke can cover only 
individual specific aspects of this multifaceted disease. A 
basic understanding of the principal molecular pathways 
induced by ischemia-like conditions comes already from 
in vitro studies. One of the most frequently used in vivo 
models in stroke research is the endovascular suture or fila-
ment model in rodents with occlusion of the middle cer-
ebral artery (MCA), which causes reproducible infarcts 
in the MCA territory. It does not require craniectomy and 
allows reperfusion by withdrawal of the occluding fila-
ment. Although promptly restored blood flow is far from 
the pathophysiology of spontaneous human stroke, it more 
closely mimics the therapeutic situation of mechanical 
thrombectomy which is expected to be increasingly applied 
to stroke patients. Direct transient or permanent occlu-
sion of cerebral arteries represents an alternative approach 
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exist [53]. For the sake of clarity, this review will focus on 
experimental models of ischemic stroke due to focal cer-
ebral ischemia only. Because of its heterogeneous etiology 
with a broad spectrum of manifestations, a large reper-
toire of models is required to address specific facets of this 
complex disorder. The deep gap between ischemic stroke 
in experimental models and the reality of stroke in human 
patients becomes painfully illustrated by the fact that with 
the exception of recanalization of the occluded vessel none 
of the hundreds of experimental neuroprotective strategies 
could be translated into the clinic up to now [61]. Never-
theless, many aspects of the pathophysiology of focal brain 
ischemia have been primarily identified in experimental 
models and could be confirmed later also in the setting of 
human stroke [90]. The development of the concept of the 
penumbra, the identification of spreading cortical depolari-
zations, the detection of post-stroke neurogenesis and the 
phenomenon of preconditioning are prominent examples of 
fruitful experimental stroke research [25].
Ischemic stroke in humans
What is the “reality” of ischemic stroke experimental 
models should depict? In humans, there are three different 
major causes for ischemic stroke. About 50% of cases are 
due to large vessel atherosclerosis and rupture of an ath-
erosclerotic plaque, while about 20% are caused by cardi-
oembolism. About 25% manifest as lacunar infarcts due to 
small vessel disease and probably occlusion of deep per-
forating arteries [9]. Some additional rare causes such as 
vasculitis or extracranial artery dissection account for the 
remaining 5% [129]. These percentages represent mean 
values over all age groups but change depending on the 
age of stroke victims. Cardioembolic stroke becomes the 
most frequent subtype with increasing age, while small 
vessel disease is rarely responsible in young people [121]. 
Furthermore, there are substantial differences in the distri-
bution of stroke subtypes among different ethnic groups 
[113]. Finally, the percentages refer to ischemic stroke 
with known etiology, but one must keep in mind that a sub-
stantial number of cases are of undetermined cause, also 
referred to as cryptogenic stroke [114]. While atheroscle-
rosis and cardioembolism frequently cause infarcts in both 
gray and white matter, lacunar infarcts are typically seen 
only in the subcortical white matter or the deep gray mat-
ter. Since these major subtypes of ischemic stroke already 
substantially differ concerning their RNA expression pro-
files in blood [62], it seems plausible that the molecu-
lar pathways and mechanisms of brain injury following 
ischemia may also be considerably different. In fact, this 
issue is currently unresolved. The neurological deficit and 
clinical presentation after ischemic stroke again exhibit a 
high variability with respect to the cause, duration, locali-
zation and severity of ischemia as well as age and comor-
bidity. One important fact in human thromboembolic stroke 
ignored in most available animal models is the occurrence 
of a substantial degree of spontaneous reperfusion, which is 
documented in up to 17% within the first hours after stroke 
onset [65]. However, reperfusion is mostly protracted but 
not prompt, thus leading to substantially different patho-
physiologic pathways. While in the former situation the 
infarct core is irreversibly damaged and the penumbra is 
consumed within about 3 h, prompt reperfusion in animal 
models may partly rescue even core tissue with second-
ary delayed injury developing up to 3 weeks after stroke 
onset depending on the ischemic interval [55]. Peri-infarct 
blood flow may also be maintained by collaterals through 
the circle of Willis and/or leptomeningeal anastomoses. 
Clinically, stroke with acute onset of symptoms must be 
distinguished from transient ischemic attacks (TIAs) where 
neurological symptoms disappear within 24 h. In contrast 
to stroke, TIAs are thought to leave no damage of brain tis-
sue, an opinion that may work conceptually but does not 
fully reflect reality [119]. In addition to acute neurological 
deficits that can be directly attributed to the affected brain 
areas, additional cognitive and psychiatric long-term conse-
quences may emerge that are not readily assignable to the 
injured brain region. Cognitive decline is a major problem 
that is often present, in particular after lacunar stroke(s), 
and is probably superimposed to the underlying small ves-
sel disease [85]. Post-stroke depression is another serious 
problem that develops in about one-third of patients with 
chronic stroke [105]. The biological basis remains uncer-
tain, which is also due to a paucity of appropriate animal 
models [75]. Another example for frequent complica-
tions of chronic stroke widely ignored in animal models is 
obstructive sleep apnea [123]. Apart from neurological and 
neuropsychiatric consequences, stroke induces an imme-
diate immune depression that is reflected by the fact that 
about 60% of stroke patients develop fever within 3 days 
after stroke onset [45]. A complex neuro-immunological 
connection consisting of the sympathetic nervous system, 
the hypothalamic-pituitary-adrenal axis and the vagus 
nerve has been identified as the biological basis [89].
Although stroke is a complex disorder, some common 
characteristics exist that can be modeled in experimental 
stroke. One important component of ischemic stroke is the 
evolving brain damage that is explained by the concept of 
the penumbra. Within minutes, reduction of the blood sup-
ply under 15–20% of baseline levels leads to an irrevers-
ibly damaged infarct core with rapidly evolving necrotic 
cell death. In the surrounding brain tissue blood flow is less 
reduced leading to loss of neuronal function while struc-
tural integrity is maintained. If there is no restoration of 
blood flow, this so-called tissue at risk will be incorporated 
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into the infarct core. The range of cerebral perfusion 
between loss of electrical activity and irreversible neuronal 
depolarization has been termed penumbra [4]. This concept 
of the penumbra has become a milestone in stroke research 
since the penumbra can principally be rescued. Using per-
fusion-weighted and diffusion-weighted MRI methods, tis-
sue at risk can be visualized by determining the perfusion-
diffusion mismatch allowing an estimation of salvageable 
brain parenchyma [31].
Therefore, it is of outmost importance to be aware of 
the strengths and weaknesses of the many available experi-
mental stroke models to choose the best one for the planned 
investigations where “best” means most closely mimicking 
a certain aspect of the multiple facets of ischemic stroke. 
One possible way to link findings in experimental stroke 
models to the reality of stroke in humans may be to add 
evidence by use of human brain tissue. For example, it 
should be tested whether findings in experimental animals 
concerning altered post-ischemic gene expression occur in 
a similar temporal, spatial and cellular pattern in human 
stroke. The same holds true for the verification at the pro-
tein level. Currently, excellent experimental stroke papers 
only sometimes include such investigations using tissue 
from one or at best a few autopsied human brains. Although 
this represents a first and important step, the quality criteria 
for experimental stroke such as blinding, randomization, 
definition of inclusion/exclusion criteria and a reasonable 
sample size calculation [66] should also be applied to the 
analysis of human autopsy cases. Failure of successful 
translation of experimental strategies into patients may also 
be caused by lack of precise information about whether 
the therapeutic target is present and regulated similarly in 
human stroke. In this context, the urgent need to build up 
large stroke brain banks becomes apparent, an issue that is 
ignored in many countries.
General issues concerning models of ischemic 
stroke
Genetic and epigenetic differences
There is a series of general issues independent from the 
choice of model potentially conflicting the reality of human 
stroke in the experimental setting. Although it may appear 
trivial, awareness of the genetic and epigenetic differences 
between mice and rats (the most frequently used animals 
in stroke research) and humans did not increase until the 
last few years. There is growing evidence that this issue 
indeed may have been given too little attention when trans-
lating results from animal experiments to human patients. 
Comparing the expression profiles by deep RNA sequenc-
ing of 15 tissues from mice and humans including brain, 
the expression for many sets of genes was found to be 
more similar in different tissues within the same species 
than between the two species [81]. Associated epigenetic 
histone marker analysis further corroborated these find-
ings. Another example for substantial differences between 
murine and human epigenetic regulation is the NOS2 gene 
in macrophages. In contrast to mice, the human NOS2 gene 
is silenced by CpG methylation, suggesting that there may 
be yet widely neglected differences between human and 
murine macrophages concerning their reaction to inflam-
matory stimuli [44]. In a most recently published proof-
of-concept study, it could be shown that both baseline 
expression of chemokines/cytokines and the response after 
oxygen-glucose deprivation in primary neurons, astrocytes 
and microglia differed significantly between rodents and 
humans [29]. It is reasonable to assume that these species 
differences may have an impact on stroke pathophysiol-
ogy. This is further corroborated by results from a multi-
plex immunoassay characterization of chemokine/cytokine 
response demonstrating significant differences after experi-
mental stroke in mice compared to the analysis of autopsy 
material from patients suffering from ischemic stroke [96]. 
Last but not least, the gut microbiome and its influence 
on the immune response is attracting growing attention. 
Although this issue may be overinterpreted currently [133] 
considering that there are already significant differences in 
the fecal microbiota of inbred strains from different ven-
dors [34], the impact on the modification and variability of 
experimentally induced diseases including stroke may be 
substantial.
Differences in brain anatomy and functional 
organization
The macroscopic differences in brain anatomy between 
humans and other species are evident at first sight. With few 
exceptions, in vivo stroke models use animals with a lissen-
cephalic brain. However, whether this difference is a major 
drawback for stroke models is under debate [20]. Neverthe-
less, the different anatomical and functional organization 
becomes relevant with respect to the infarct localization. 
While in animal models the main focus is frequently on 
infarct size, this reflects reality in human conditions only 
to a limited extent. The localization of the ischemic lesion 
within particular connections may be more relevant for the 
clinical syndrome and long-term outcome (Fig. 1). Another 
serious issue is the low extent of white matter in rodents 
compared to humans. While in humans the percentage of 
white matter accounts for 60%, it decreases to about 35% 
in dogs, 20% in rabbits, 15% in rats and is as low as 10% in 
mice [73] (Fig. 1). However, ischemic damage of the white 
matter plays an important role for the prognosis of stroke 
outcome and is the major cause of hemiparesis in all three 
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major stroke subtypes [1]. In a very recent study the rele-
vance of remote white matter integrity for long-term cogni-
tive outcome has been clearly demonstrated [110]. In lacu-
nar stroke, white matter damage even plays the central role. 
Furthermore, while the differences in the complexity and 
functional organization of the brain are less problematic 
when analyzing the molecular and cellular responses after 
acute ischemic stroke, it becomes a major issue in models 
of chronic stroke where recovery of function and neuropsy-
chiatric long-term consequences are of particular interest. 
Interestingly, although pronounced lateralization of brain 
function is one feature of human brains, it is also already 
present in rodents. While rats subjected to right MCA 
occlusion exhibited transient hyperactivity, this effect was 
not seen after occlusion of the left MCA [104].
Differences in vascular anatomy
To protect the human brain from fluctuations of blood 
supply, several safeguards have merged during evolu-
tion. First, redundancy of cerebral perfusion is provided 
by three collateral systems in the cerebral vasculature. 
One principal shunt exists between the branches of the 
extra- and intracranial arteries. Furthermore, the circle of 
Willis at the base of the brain with connections between 
the anterior and posterior circulation as well as between 
the left and the right hemisphere allows redirection of 
the blood flow when one artery becomes occluded. How-
ever, a high interindividual variety of the circle of Willis 
has been shown in many studies with a completely normal 
configuration only in a minority of cases without evi-
dence for ethnic differences [32]. The most complex col-
lateral system is represented by a highly interconnected 
dense network of leptomeningeal vessels protecting in 
particular cortical structures unless blood pressure is high 
enough [12]. Second, at a functional level perfusion can be 
regulated by autoregulation of cerebral resistance arteries 
and endothelial regulation of the vascular tone by releas-
ing vasoconstrictive or vasorelactant molecules. Neuronal 
activity is also closely linked to enhanced perfusion a phe-
nomenon termed neurovascular coupling [91]. It is imme-
diately apparent that alterations and even variations in 
these systems will influence survival of brain tissue after 
focal ischemia, and it is also obvious that differences in 
these systems between species will result in different pat-
terns of ischemic damage.
Although the principle plan of vascular organization 
is present in all mammalian brains, there is a broad spec-
trum of variations between species and even strains con-
cerning the number and diameter of collaterals in arterial 
trees and the capacity for remodeling after vessel occlu-
sion (Fig. 2). In C57Bl/6J mice, for example, a complete 
circle of Willis is present in only 10% [88]. Compared to 
BALB/c mice, substantial differences are present in the 
total collateral system with candidate genes predominantly 
on chromosome 7 identified in association mapping stud-
ies and suggesting a high polymorphism [127]. Similarly, 
a genetic background could recently be related to varia-
tions in the circle of Willis of gerbils [80]. Wistar rats have 
been shown to possess thinner posterior communicating 
Fig. 1  Illustration of connectivity as obtained by 3D-polarized light 
imaging (3D-PLI) [5, 6, 139]. Coronal sections from a human brain, a 
vervet (monkey) and a rat brain. The color sphere indicates the direc-
tion of fibers; black corresponds to a steep course of fibers in the third 
dimension, within the physical section. The comparison illustrates 
that not only the absolute volume of brains differs among the three 
species, but also the relative amount with a much higher proportion 
of white matter in human brains as compared to vervet and rodent 
brains. (Images by courtesy of Markus Axer, Karl Zilles and Katrin 
Amunts, Forschungszentrum Jülich, Germany)
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arteries than Sprague-Dawley rats [68]. Sprague-Dawley 
rats on the other hand have atypical branching of the MCA 
in nearly 20% [38]. This partly explains the high variance 
of infarct sizes even in the same species or strain after 
occlusion of an artery. Another aspect is that the variability 
of the vascular anatomy impedes specific models of artery 
occlusion. Due to a network of freely anatomizing arteries, 
the so-called “rete mirabile,” a proximal occlusion of the 
MCA for infarct induction, is not suitable in larger animals 
such as cats, dogs, sheep, goats and pigs [56]. In contrast, 
collateral blood flow in rodents after MCA occlusion is 
generally poor [54].
While differences in the gross anatomy of arteries and 
collaterals may cause only variations in brain injury pat-
terns, functional differences may have deeper implica-
tions concerning the pathophysiology of the ischemic cas-
cade. At least for neurovascular coupling after ischemic 
stroke differences between humans and animals have been 
described with generally impaired functional hyperemia 
in animals but variable findings in stroke patients [60]. 
Another structure playing a key role in the pathophysiology 
of stroke is the blood-brain barrier (BBB). Vessel occlu-
sion with breakdown of the supply with oxygen and glu-
cose damages not only neurons and glial cells resulting in 
cytotoxic brain edema, but also injures the BBB itself addi-
tionally causing a vasogenic brain edema. There is some 
evidence that ischemic damage of the BBB in humans may 
primarily involve other components of the vascular tree. 
While in both mice and rats albumin extravasation could 
be identified around arteries, capillaries and veins in human 
autopsy tissue, the capillary compartment was relatively 
spared [76].
Differences in the immune system
While in the last decade much interest focused on the 
inflammatory response after stroke, the differences between 
rodents and the real situation in humans are immense. This 
starts with the simple fact that the percentage of neutrophils 
in mice and rats is about 10–20% compared to 50–70% in 
humans, while the opposite situation is seen for lympho-
cytes, which comprise about 50–100% in rodents compared 
to 20–40% in humans, respectively [47]. Moreover, there 
is only a minimal intersection of whole-genome mRNA 
and microRNA expression in leukocytes from rodents ver-
sus humans at both baseline and after stroke, raising the 
question whether rodents are acceptable models at all for 
the human immune system after stroke [116]. The subnet-
works of chemokines/cytokines in human, mouse and rat 
brain cells differ after in vitro ischemia [29], and there are 
important differences between microglia from rodents and 
humans [118]. How minimal differences in the immune 
system even between—compared to rodents—relatively 
closely related species, namely the gyrencephalic cynomol-
gus macaque and humans, may cause substantially different 
responses became dramatically apparent in the TGN1412 
trial. In 2006, six healthy volunteers suffered from a life-
threatening incident by developing a cytokine-release 
syndrome with multiple organ failure in a phase I clinical 
trial after administration of the CD28 super agonist anti-
body TGN1412, an immunomodulatory drug. In contrast 
to CD4+, T cells of humans expressing CD28 macaques 
lost CD28 expression of CD4+ T cells during differen-
tiation [58]. This detail has been overlooked in preclini-















Fig. 2  Imaging of the human (a) and murine cerebrovascular sys-
tem (b). Although the principle plan of cerebrovascular organization 
is similar in humans (a) and mice (b), some differences exist. The 
BA, for example, in humans most often terminates by splitting into 
the PCA, whereas in mice the BA in most cases terminates by split-
ting into the SCA (with the PCA originating from the ICA). Also, in 
humans the postcommunicating ACAs normally are paired, whereas 
mice feature an azygos ACA. a Time-of-flight MR angiography 
showing the human arterial cerebrovascular system, (maximum inten-
sity projection, AP view); b in vivo digital subtraction angiography 
(DSA) of the murine cerebrovascular system [35, 111]. Images cour-
tesy of Prof. Marc A. Brockmann, Department of Neuroradiology, 
University Medical Center of the Johannes Gutenberg University, 
Mainz, Germany. ACA anterior cerebral artery, BA basilar artery, ICA 
internal carotid artery, MCA middle cerebral artery, PCA posterior 
cerebral artery, SCA superior cerebellar artery, VA vertebral artery
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although the dose in monkeys was up to 500 times higher. 
Since inflammation after ischemic stroke is thought to play 
a crucial role in the pathophysiology of the ischemic cas-
cade and also with regard to the final outcome, one should 
always be aware of the potential fundamental differences 
between animal models and reality.
Characteristics of experimental animals
Perhaps the most obvious discrepancy between reality and 
experimental stroke models is the difference in the popu-
lations analyzed. Ischemic stroke in humans preferentially 
occurs in elderly patients of both sexes with often multiple 
comorbidities (diabetes mellitus, hypertension, hyperlipi-
demia, obesity) requiring multiple medications with mul-
tiple complex interactions. In contrast, the vast majority of 
experimental stroke studies have been performed on young, 
healthy, male inbred rodents housed under optimal patho-
gen-free conditions [24]. Experiments are performed under 
highly standardized and very well-controlled conditions 
to reduce the variability of infarct size to a minimum. In a 
recent review on strain-related differences in the immune 
response and the relevance to human stroke, Becker [11] 
provocatively but concisely formulated: “… almost all 
of what we know about the role of the immune system in 
stroke is derived from a single line of inbred mice.”
Anesthesia
Another basic difference between experimental models and 
the reality of stroke occurring in humans is the use of anes-
thesia in the majority of animal models. Apart from periph-
eral effects, including the influence on blood pressure, 
cerebral blood flow and metabolism, anesthetics may have 
neuroprotective effects, thus modulating some aspects of 
spontaneously occurring post-ischemic processes [69, 71].
In vitro models of ischemic stroke
It is clear that the complex situation of ischemic stroke 
cannot be modeled in an in vitro system with single cells 
or pieces of brain tissue with the absence of intact blood 
vessels and blood flow as well as the lack of infiltration 
of leukocytes. Nevertheless, in vitro models allow the 
investigation of specific basic biochemical and molecular 
mechanisms under conditions of energy deficiency similar 
to ischemia. The fundamental critical control points and 
molecular pathways of necrotic cell death, programmed 
cell death and autophagy are also amenable to direct 
study in vitro [52]. Another advantage of in vitro mod-
els is the possibility of high-throughput analyses, which 
becomes relevant with respect to testing novel potentially 
neuroprotective pharmaceuticals. In this context, the pos-
sibility to use human or humanized cells becomes increas-
ingly important.
There are two principal ways to induce ischemia-like 
events outside a living organism: either the deprivation of 
oxygen and glucose or the chemical or enzymatic block-
ade of the cellular metabolism. The most frequently used 
in vitro model of cerebral ischemia is the combined oxy-
gen and glucose deprivation (OGD). To this end, the atmos-
phere in the incubator with cultured cells or brain slices 
is exchanged. The normal O2/CO2 equilibrated medium is 
replaced by an N2/CO2 equilibrated medium in a hypoxic 
chamber with glucose omitted from the medium. Retaining 
glucose in the hypoxic chamber is termed hypoxia and is 
less suitable for modeling an ischemic event, which always 
is accompanied by breakdown of the nutrient supply. Com-
pared to in vivo models, there is characteristically a need 
for a longer episode of energy deficiency to induce neu-
ronal death. Typically, cell cultures are exposed to OGD 
for 1–24 h. In contrast to single-deprivation paradigms, 1 h 
exposure to OGD is already sufficient to induce widespread 
neuronal death [42]. Modeling ischemia-reperfusion can 
be achieved by a return to standard culture conditions. A 
particular aspect of the ischemic cascade is excitotoxicity, 
resulting from an increase in glutamate with consecutive 
overactivation of glutamate receptors. In vitro models allow 
for an isolated analysis of this specific component of the 
ischemic cascade by exposing the culture to glutamate or 
other specific agonists of excitatory receptors [19].
A broad repertory of cellular systems to model in vitro 
ischemia exists, excellently reviewed by Holloway and 
Gavins [52]. The two main cellular platforms, organotypic 
brain slices and primary cell cultures, respectively, will 
briefly be introduced. The organotypic brain slice has the 
advantage of a functional system with preservation of the 
neuronal morphology and the presence of glial cells and 
network connections in particular when using hippocam-
pal slices. On the one hand, lack of perfused vessels in 
brain slices clearly represents an artificial situation that on 
the other hand allows separating the ischemic effects on 
neuronal tissue from those due to actions on the cerebro-
vascular system [28]. Since all in vitro systems primarily 
mimic the situation of global cerebral ischemia, there are 
attempts to more closely model the situation of ischemic 
stroke, i.e., focal cerebral ischemia [101]. To this end, OGD 
medium is only focally applied to the brain slice while 
the rest is kept in normal oxygenated media. Interestingly, 
neurons adjacent to the OGD core progressively depolar-
ize, a phenomenon seen in the penumbra in vivo. Thus, 
the situation comes closer to the situation of focal cerebral 
ischemia. Most importantly, brain slices can also be pre-
pared from human brain tissue and exposed to OGD exper-
iments [102]. To study the cell-specific responses to stress 
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such as OGD, the use of primary neuronal and glial cells 
is an invaluable benefit to understand their specific roles in 
stroke pathophysiology. These studies represent an impor-
tant component of preclinical stroke research but have to 
be combined with in vivo experiments to come closer to 
the reality of human stroke. Modeling the BBB is another 
important in vitro approach to understand one structure 
that plays a key role in stroke pathophysiology. Since it 
has become clear that the BBB is only one component of 
the neurovascular unit consisting of endothelial cells, peri-
cytes, astrocytes, oligodendrocytes, microglia and neurons, 
i.e., practically any cell type in the brain [22], most recent 
approaches try to model this complex system with all com-
ponents three-dimensionally in vitro [3].
Rodent models of ischemic stroke
While in the beginning of experimental stroke research 
mainly higher species were used, this situation has com-
pletely changed within the last 3 to 4 decades. Today, 
mostly mice and rats are chosen for in vivo stroke models, 
which is easy to understand considering the lower costs of 
acquisition and keeping, simpler monitoring methods and 
tissue processing as well as ethical issues. The possibility 
to easily create transgenic animals is another major advan-
tage of mouse models. However, one always has to keep 
in mind that the results of rodent models of stroke may 
only be half the truth. Due to the constant failure to trans-
late experimental neuroprotective therapies into patients, 
the “stroke community” stands in the forefront of critically 
scrutinizing to what extent experimental models reflect 
reality. Starting with the STAIR recommendations 1999 
[122], a series of landmark reviews considering this issue 
and providing recommendations to model stroke more 
realistically in the experimental setting has been published 
[26, 33, 36, 84]. In particular, there is the strong advice to 
reproduce successful stroke therapy in rodents in a higher 
species before starting clinical trials. The following para-
graphs will briefly discuss the most important models with 
a focus on differences and similarities to the situations in 
humans (Table 1). For an extensive and excellent overview 
of currently available models with a focus on methodologi-
cal aspects, see [23].
Intraluminal suture MCAO model
The most frequently used experimental model of ischemic 
stroke in rodents is the intraluminal suture middle cerebral 
artery occlusion (MCAO) model, which does not require 
craniectomy. To induce vessel occlusion, a monofilament 
is introduced into the internal carotid artery and advanced 
until the origin of the MCA is blocked. This method was 
developed and first described by Koizumi and colleagues 
[72] in rats followed by multiple modifications particularly 
concerning the kind, coating and length of the filament 
as well as modifications of the access route (e.g., [82]). 
Meanwhile, the model has also been adopted for mice and 
is increasingly applied there [49]. Principally, the suture 
model can be used to model permanent ischemia or by 
withdrawal of the filament with subsequent reperfusion as 
a model for transient focal cerebral ischemia with variable 
reperfusion time points. Typically, reperfusion intervals 
range between 60 and 120 min in rats, resulting in delayed 
neuronal death or pannecrosis of large parts of the ipsilat-
eral hemisphere, respectively. Since most thromboembolic 
infarcts in humans occur in the territory of the middle 
cerebral artery (MCA) [98], this model closely resembles 
manifestation of human stroke concerning the localiza-
tion (Fig. 3). Inherent to this model is involvement of the 
hypothalamus after occlusion times of 120 min or longer in 
rats resulting in spontaneous hyperthermia, which is rarely 
seen in humans [41, 79]. Concerning the infarct sizes, 
Carmichael pointed out that the suture MCAO method in 
rodents may frequently model malignant infarction with 
progressive edema rather than most cases in humans with 
comparatively small infarcts [16]. Although the intralumi-
nal suture model has provided substantial knowledge of 
the pathophysiology of cerebral ischemia in particular con-
cerning the ischemic penumbra, blood-brain barrier injury, 
inflammatory processes and cell death pathways, it has a 
serious inherent problem. In human ischemic stroke, ves-
sel occlusion is frequently not complete, and at least par-
tial spontaneous reperfusion due to successive resolution 
of the thrombus occurs in most patients in the first 48 h 
after stroke [65, 137]. In contrast, withdrawal of the fila-
ment in the suture model results in an ad hoc reperfusion. 
This entails induction of molecular and cellular mecha-
nisms more similar to the situation after global ischemia 
but is entirely different compared to the human situa-
tion. Although it is currently the most frequent model of 
ischemic stroke, on a somewhat more critical note, one can 
say that it does not fit any of the three major subgroups of 
stroke with regard to the etiology. In a provocative opin-
ion article, it was suggested to take this model completely 
out of the repertoire of stroke models because its clinical 
relevance in particular with respect to translational aspects 
is poor [55]. Even rtPA-induced lysis of a thromboembolic 
occlusion is associated with prolonged reperfusion deficits. 
However, the suture model may closely mimic the situa-
tion of interventional mechanical thrombectomy. In 2015, 
five multicenter randomized clinical trials were published 
demonstrating beneficial effects of endovascular therapy of 
ischemic stroke due to large vessel occlusion [43]. In light 
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of these results, increasing clinical use is to be expected 
making the filament model indeed more relevant for this 
specific condition.
Craniectomy models
Another principal possibility for induction of focal 
ischemia is to directly occlude a cerebral vessel. If this is 
done by clipping, ligation or with hooks, reperfusion is 
principally possible. Cauterization followed by transection 
on the other hand results in permanent ischemia. All these 
direct approaches have in common that a craniectomy with 
incision of the dura mater is necessary. This distorts the 
reality of human stroke in so far as craniectomy represents 
a kind of skull trauma that may induce cortical spreading 
depressions and inflammation. In unfavorable cases, the 
brain itself may be directly injured by the drill or thermally 
damaged by electrocoagulation of a vessel. Due to the 
opening of the dura, the brain is exposed to the atmosphere, 
the intracranial pressure is affected, and changes in regional 
brain temperature may occur [23]. The first description of 
MCA occlusion via a direct approach was made by Rob-
inson et al. [106] in Sprague-Dawley rats using ligation of 
the distal MCA to induce cortical ischemia. Tamura devel-
oped a model with a more proximal occlusion of the MCA 
resulting in infarcts in the cortex and striatum similar to the 
suture model but without the hyperthermic response [125]. 
Two of the most frequently used modifications are the tan-
dem vessel occlusion with electrocoagulation of the distal 
MCA plus unilateral common carotid artery (CCA) occlu-
sion [14] or the so-called three-vessel occlusion model with 
additional bilateral CCA occlusion [18] resulting in large 
cortical infarcts with high mortality. These craniectomy 
models with their multiple variations are used in many 
species including non-human primates. One has to keep 
in mind that prompt reperfusion by reversible mechanical 
occlusion comes up with the same problem discussed for 
the suture model. The pathophysiological consequences 
are far from the reality of ischemic stroke in humans with 
spontaneous or rtPA-induced opening of the occluded ves-
sel [55].
Models of ischemic stroke in the posterior cerebral cir-
culation to mimic vertebro-basilar stroke are technically 
elaborated and are mostly performed in large animals. A 
vertebro-basilar stroke model in the rat has been described 
by Henninger et al. [50].
Photothrombosis model
The photothrombotic stroke model (synonymously also 
named the photochemical stroke model) has been primar-
ily developed in rats [130], but meanwhile modified pro-
tocols for mice are available [67]. For stroke induction, 
a photosensitive dye (e.g., Rose Bengal) is systemically 
applied followed by illumination of the brain through 







Fig. 3  Media infarcts in human (a, c) and rat brain (b). An acute 
ischemic stroke in the territory of the middle cerebral artery (MCA) 
in a human brain (a; asterisk infarct). Such acute large media infarcts 
are easily modeled with the filament technique (b; rat, 120 min tran-
sient ischemia, 24 h survival; TTC stain: vital tissue red, white tis-
sue (asterisk) indicates infarct; inset: real proportions of the rat brain 
compared to human brain. Chronic infarcts (c, human) of similar 
sizes in rodents rarely come to examination
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illumination activates the dye leading to the formation of 
singlet oxygen and superoxide, which in turn results in 
endothelial injury, platelet activation and aggregation. This 
causes rapidly evolving ischemic cell death in the illumi-
nated brain area in end arterial regions eventually leading to 
a cortical ischemic lesion. Whether platelet activation really 
plays a major role is a matter of debate, so “photothrom-
botic” model may indeed be a misnomer [70]. One advan-
tage of this model is the possibility to select a specific cor-
tical brain region of interest for the ischemic lesion because 
of the use of stereotactic coordinates and application of the 
activating light at the desired area. Another advantage is its 
high reproducibility or the other way around the minimal 
variation in infarct size combined with very low mortality. 
This makes it a predestined model to study repair mecha-
nisms and related long-term functional outcome [21, 39]. 
The major issues with this experimental model are funda-
mental discrepancies compared to the situation in acute 
human stroke. While the latter is characterized by a primar-
ily cytotoxic edema [109], photothrombotic stroke induces 
a nearly simultaneous development of cytotoxic and vascu-
lar edema with rapid breakdown of the blood-brain barrier. 
The second major drawback is a virtual lack of a penumbra 
and collateral blood flow. Since the penumbra or the tissue 
at risk is the major target of any neuroprotective therapy, 
the translational impact of this model is poor. Modifica-
tions of the classical model have been developed to mimic 
also a penumbral region. Adapting the illumination param-
eters by use of a ring filter (the so-called “ring model”) 
results in a central area without thrombosis surrounded 
by damaged brain [131], but whether this adequately cor-
responds to the penumbra in the human situation is under 
discussion [16]. Other modifications include the targeting 
of individual brain arterioles or the induction of small sub-
cortical infarcts by implanted optical fibers to model lacu-
nar stroke. Another interesting approach is the induction 
of photothrombotic stroke in freely moving rats and mice, 
which allows real-time analysis of a number of parameters 
in acute stroke without distortion by anesthesia [83, 136].
Endothelin‑1 model
Endothelin-1 is a peptide with potent and long-lasting 
vasoconstrictive properties [135]. Application onto an 
exposed vessel or directly on the brain surface or stereotac-
tically injected into the brain parenchyma leads to vasocon-
striction inducing downstream ischemia [37]. Using this 
method, more or less any region in the brain is targetable. 
Depending on the concentration of endothelin-1, the sever-
ity and duration of ischemia as well as the resulting infarct 
size may be modified. When the endothelin-1 effect eases, 
blood flow is gradually reestablished, thus representing the 
situation of transient focal ischemia. The model has been 
developed in rats [103] and modified for the use in mice 
[107, 120]. Although endothelin is considered to play a 
key role in the induction of vasospasms after subarachnoid 
hemorrhage with subsequent infarcts in human patients, 
there are no data on its application in animal experiments 
to model this specific situation. Since ischemia develops 
slowly after endothelin-1 application and is accompanied 
only by minimal edema, this model again does not accu-
rately mimic human stroke [112]. Similar to the photo-
thrombotic model, it may be more useful for simulating 
lacunar stroke and for long-term studies with a focus on 
recovery mechanisms. However, endothelin-1, endothelin-
1-converting enzyme and endothelin-1 receptors are not 
only expressed by endothelial cells, but are also present on 
neurons and astrocytes [94, 95]. Even more, endothelin-1 
application has been shown to induce proliferation of astro-
glia, producing a permissive milieu for enhanced axonal 
sprouting, which may interfere with post-stroke recovery 
mechanisms [16].
Embolic stroke models: thromboembolic clot models
Embolic stroke models fall in two major categories: 
thromboembolic clot models and non-thromboembolic, 
microsphere or macrosphere-induced stroke models. All 
the variants of embolic stroke models go back to the first 
description of a thromboembolic infarct model in rats by 
Kudo et al. [77]. Apart from the general issues of animal 
models mentioned above, the clinical reality of human 
embolic stroke is in fact best modeled using any kind of 
embolus-like material that is introduced into the cerebral 
vessel system, typically in the extracranial internal carotid 
artery (ICA) or a stump of the external carotid artery 
(ECA). In thromboemblic models, the clot can be gained 
from spontaneously formed or thrombin-induced throm-
botic material, mostly from autologous, but also from het-
erologous blood [30]. Depending on the size and number of 
clots as well as the application route, this will cause occlu-
sion of one or multiple vessels followed by infarcts in the 
respective supplied territory. Alternatively, thrombin can 
be directly injected into the ICA or MCA to mimic vascu-
lar occlusion. However, the composition of the clot differs 
substantially from that in humans since it consists primarily 
of fibrin with only few cells that may influence spontane-
ous or therapeutically induced lysis [99].
Similar to the situation in humans, there is a high degree 
of variation in the infarct localization and infarct size. More 
importantly, there is unpredictable partial or complete lysis 
of the occluding material followed by reperfusion, which 
resembles the clinical situation more closely compared to 
all the other experimental situations. Thromboembolic clot 
models are therefore ideal for analysis of spontaneous or 
iatrogenic lysis by rt-PA. The pathophysiology of embolic 
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stroke in animals perfectly matches human embolic stroke 
including primarily cytotoxic edema superimposed later 
on by vasogenic edema with breakdown of the blood-brain 
barrier, presence of a penumbra, development of spreading 
depressions as well as an inflammatory response [54]. Not 
only the acute but also the chronic phase with spontaneous 
recovery mechanisms can be analyzed. This advantage of 
great similarity goes along with the disadvantage of great 
variability and consequently the need for higher numbers of 
animals to achieve statistically meaningful results. This led 
to the development of embolic material not lysable for bet-
ter standardization but at the price of departing from reality.
Embolic stroke models: microsphere/macrosphere 
stroke models
Many different materials such as silicone, collagen or tita-
nium dioxide (TiO2) have been used for embolic stroke 
induction in animal models [30]. The basic difference com-
pared to the thromboembolic clot model is that the artifi-
cial spheres do not dissolve and therefore cause permanent 
ischemia. Microspheres have a diameter of 20–50 µm and 
cause microembolization of multiple vessels resulting in 
multifocal and heterogeneous infarcts that develop up to 
24 h after injection [87]. Primarily developed to mimic 
transient ischemic attacks, it can also be used to induce 
graded infarcts depending on the size and number of 
emboli [54]. The pathophysiology, however, differs from 
the typical human condition of embolic stroke with occlu-
sion of one artery. In the microsphere model, capillaries 
and arterioles are blocked resulting in redistribution of the 
blood flow and immediate disruption of the blood-brain 
barrier and vasogenic edema [132].
Macrospheres have diameters between 300 and 400 µm, 
which are installed in the ICA and result in well-defined 
infarcts in the MCA territory [40]. Again, the severity of 
the ischemia and infarct size can be shaped by the number 
of up to six macrospheres. Kinetics of infarct development, 
lesion site and infarct size as well as outcome are similar 
to the intraluminal suture model. However, the hypotha-
lamic artery is not blocked, and, compared to the intralumi-
nal suture model, hyperthermia due to hypothalamic injury 
does not develop. An advantage of this model is that the 
occlusion can be postponed, allowing to induce ischemia 
while the rat lies in an MRI or PET scanner (review by 
[126]).
Modeling risk factors and comorbidity
In particular, the persistent failure to translate successful 
neuroprotective strategies in rodents or even non-human 
primates into human patients suffering from ischemic 
stroke led to critical reflections about whether the animal 
models used are indeed suitable to cover the reality of 
human stroke [33]. Apart from possible experimental qual-
ity problems, the use of young, healthy, male rodents in the 
overwhelming number of experiments is a major distorting 
factor. Therefore, in the last years numerous attempts have 
been made to use animal models with the most frequent 
comorbidities such as diabetes mellitus, hypertension, ath-
erosclerosis, hyperlipidemia, obesity or infection for stroke 
research. Further, aged animals and animals of both sexes 
have been used to capture reality more accurately. Age is 
the single most unmodifiable risk factor for stroke. From 
experimental studies with aged animals, it has become 
clear that neurological impairment increases, whereas the 
regenerative capacity is lowered compared to younger ani-
mals (for review, see [15]). There is growing evidence that 
the common link of age and the various modifiable risk 
factors mentioned above may be an elevated inflammatory 
profile resulting in a stroke-prone state [93, 108]. Sex is 
another important factor significantly affecting stroke inci-
dence and outcome [51].
When modeling risk factors of stroke, two principal 
experimental strategies are available. The most realistic 
approach would be to develop animal models with inher-
ent risk factors that eventually result in spontaneous stroke. 
This approach is widely restricted to animal models of 
hypertension. Although closely mimicking the situation 
of human stroke, these models are costly and extremely 
time-consuming. The other principal option is to induce 
ischemic stroke in animals (or stroke-like conditions in 
in vitro systems) with preexisting comorbidities. The stroke 
models per se are principally the same as described in the 
above paragraphs. The major challenge in designing exper-
imental ischemic stroke is to find a good balance between 
the high complexity of multiple interacting parameters as 
in humans and pragmatically manageable studies deliver-
ing good results for specific scientific problems.
Spontaneous stroke models
Since hypertension is the single most important modifiable 
risk factor for stroke in humans [2], the use of hypertensive 
animals for stroke research is a step in the right direction to 
create a more accurate situation of clinical reality. The mod-
els most frequently used are the spontaneously hypertensive 
rat (SHR) and the stroke-prone spontaneously hypertensive 
rat (spSHR), which were developed about 50 years ago by 
Okamoto and Aoki [97]. The SHR is a selective inbreed 
from Wistar-Koyoto rats that developed the highest blood 
pressure values, while the spSHR is one substrain of the 
SHR. This phenotype selection, however, precludes appro-
priate controls matched for both hypertension and genetic 
background. The SHR is normotensive at birth and develops 
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hypertension because of an overactivity of the renin-angi-
otensin system between 2 and 4 months settling at systolic 
values of about 200 mmHg by 6 months. While the SHR 
rarely suffers from spontaneous stroke, the spSHR devel-
ops hypertension under a high-salt diet from the age of 6 
weeks, which rapidly aggravates to malignant hypertension 
(>240 mmHg) by 12 weeks accompanied by cortical strokes 
and hemorrhages in the frontal, parietal and occipital regions 
by about 20 weeks [8]. The spSHR also develops small sub-
cortical infarcts in the striatum and subcortical white matter 
because of hypertensive small vessel disease with arteriolar 
wall thickening, fibrinoid necrosis and enlarged perivascu-
lar spaces similar to the human pathology [7]. Pathophysi-
ologically, the first step seems to be an alteration of the 
endothelial tight junctions that occurs before hypertension 
and hypertension-related vessel changes or even ischemic 
lesions develop, a mechanism quite controversially dis-
cussed for human small vessel disease [8, 10, 13, 48, 128]. 
A certain degree of caution with the translation of the find-
ings in spSHR is also indicated when considering that due 
to the unpredictable onset of stroke the discrimination 
between causative and reactive changes may be not always 
clear. Also noteworthy is the fact that there are already sub-
stantial differences in vessel structure between spSHR and 
SHR compared to their Wistar-Koyoto parent strain. The 
media-to-lumen ratio in the cerebral arteries is increased in 
SHR and spSHR compared to Wistar-Koyoto rats, which 
may be a risk factor under reduced cerebral blood flow with 
significant changes in pathophysiology and outcome [64]. 
Nevertheless, the spSHR is currently by far the best animal 
model for lacunar stroke in humans because of the similar-
ity of the underlying small vessel disease [46]. For the sake 
of completeness, other spontaneous stroke models such 
as the male-inducible hypertensive rat or (R+/A+) mice, 
which are double transgenic for the human renin and human 
angiotensinogen genes, are available, which also develop 
spontaneous ischemic and hemorrhagic cerebral lesions 
after induction with specific diets [46].
Special comment on non‑human primate models
Non-human primates may have a lissencephalic brain, like 
the common marmoset and the squirrel monkey, or they 
may possess gyrencephalic brains, like the baboon, the 
Rhesus macaque and the Cynomolgus macaque, to mention 
the most relevant species in the context of stroke models. 
Of all primates, the macaque monkeys most closely resem-
ble the human brain concerning anatomy with a specific 
cortical and subcortical organization, but most important 
for stroke research also with regard to vascular supply and 
collateralization [20]. Nevertheless, currently it is unclear 
which non-human primates most closely mimic the human 
conditions of stroke.
For a long time, above all the baboon model has been 
used in stroke research. Although these non-human pri-
mates have a gyrencephalic brain, the rich collateralization 
compared to humans demands relatively complex tech-
niques for stroke induction with many modifications avail-
able [78]. Typically, a transorbital route with enucleation 
of the eye has to be performed to get access to the MCA 
and both anterior cerebral arteries to induce infarcts in the 
cortex and subcortical white matter [57]. This, however, 
prevents post-stroke behavioral tests requiring binocular 
vision. Depending on the stroke syndrome to be mimicked, 
all the various models of ischemia induction are princi-
pally possible including endovascular models with balloon 
occlusion [134] similar to the suture model in rodents.
Although one would intuitively postulate that experi-
mental stroke in non-human primates is closer to the situ-
ation in humans, there are some data that may make one 
thoughtful. Apart from one single study, there is a lack of 
direct comparison of stroke models in rodents, non-human 
primates and humans. Here, comparing detection of DNA 
damage after MCA occlusion in rats and baboons, distinct 
temporal, spatial and quantitative differences were detect-
able in the corpus striatum [124]. Neuronal cell death in 
the primates occurred more rapidly than in rats, being 20 
times higher already after 2 h but was nearly identical at 
20 h. It is suggested that the baboon data more likely reflect 
the situation in humans, but clear evidence is lacking. More 
unsettling is the situation when looking at neuroprotective 
trials. Lysis of an occluded vessel, the first and only stroke 
therapy successfully translated from an animal model into 
patients, was adapted from a rabbit model of stroke [140]. 
On the other hand, NXY-059, which exhibited promising 
neuroprotective effects in rodent stroke models, was posi-
tively replicated in the common marmoset [86] according 
to the advice of STAIR before going to clinical trials. How-
ever, when it came to clinical studies, it failed to show a 
neuroprotective effect [117].
Nevertheless, it is also clear that ischemic brain injury in 
non-human primate species results in a clinical syndrome 
that more equally reflects post-stroke deficits in humans. 
Currently, major efforts are undertaken to transfer mouse 
transgenic techniques to non-human primates (for review, 
see [59]). New genome editing tools such as the CRISPR/
Cas9 system [63] will principally enable researchers in the 
near future to manipulate gene expression cell-type specifi-
cally in non-human primates. Given the much higher simi-
larity to humans in brain structure and function compared 
to rodent animal models, one may expect a deeper under-
standing of the pathophysiology of stroke—and, much more 
importantly, will be able to translate this knowledge into 
effective therapies of ischemic stroke in both the acute and 
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chronic state. Apart from the highly expensive housing of 
these nonhuman primates, the major issue will be whether 
society will go along and accept the idea that these experi-
ments are ethically acceptable. The various aspects of ethical 
issues are critically reviewed by Cook and Tymianski [20].
Animal models of post‑stroke recovery 
and long‑term post‑stroke complications
Although mechanisms of spontaneous recovery after 
stroke have been studied in both rodents and humans for 
a long time [27, 115], the frustrating translational fail-
ure of neuroprotective strategies in acute stroke gave 
new impetus toward studies on neuroregeneration. The 
challenges in models of post-stroke recovery differ from 
those in acute stroke models. Well-standardized lesions in 
defined brain areas are necessary to record the plasticity 
processes. Although principally the complete repertoire 
of stroke models can be used, the more suitable ones go 
along with low mortality and the possibility to produce 
small and standardized lesions. The peri-infarct cortex, 
closely connected ipsilateral areas but also contralateral 
and remote regions are of particular importance. There-
fore, in particular the photothrombosis model and the 
endothelin-1 model have been used to analyze recovery 
processes. Although the principal events leading to post-
stroke recovery are widely concordant in humans and 
animals, the kinetics differ considerably. While recov-
ery processes in rodents are almost completed 4 weeks 
post-stroke, in humans they primarily occur within about 
3 months but may even continue for years (for review, 
see [17, 138]). The exact reason for this difference is not 
known up so far [74].
Of utmost importance is the use of behavioral tests in the 
long run, which should ideally test for sensorimotor perfor-
mance, cognitive performance and mood changes. This is 
also one big difference between experimental models and 
reality. While multiple studies focus on the first days after 
stroke, the final degree of disability in human patients typi-
cally is measured months to years after the ischemic event. 
On the other hand, chronic stroke comes along with com-
plications that have also led to the development of spe-
cific models. One frequent event in more than one-third of 
stroke survivors is the development of a post-stroke depres-
sion. The biological basis is yet widely unclear. A number 
of models have developed to specifically cover this prob-
lem [75]. Another frequent complication in up to 30% of 
stroke patients is development of epileptic seizures and a 
prevalence of post-stroke epilepsy of 2–4%. Spontaneous 
epilepsy in rats develops in up to 15% with high variability. 
Specific models for post-stroke epilepsy are rare [100].
Conclusion
On the one hand, ischemic stroke is principally a simple 
and well-defined pathological condition with interruption 
of blood flow and consecutive damage of dependent tis-
sue. One the other hand, however, ischemic stroke is a very 
complex and heterogeneous disorder because of a multi-
tude of modifying factors such as the duration and sever-
ity of ischemia, presence or absence of functioning col-
lateral systems and an adequate systemic blood pressure, 
etiology and localization of the infarct as well as age, sex, 
comorbidities with multimedications and genetic back-
ground. Strictly speaking, stroke is not a single neurologi-
cal disease but the manifestation of an underlying systemic 
problem such as atherosclerosis, inflammation or infection, 
which may cause infarcts just as well in other organs and 
manifest, e.g., as a heart attack. Experimental models of 
ischemic stroke are valuable tools to analyze specific facets 
of stroke more or less close to human stroke. Being aware 
of the limitations of the individual models and ideally hav-
ing support from studies using human tissues are of utmost 
importance before drawing conclusions concerning stroke 
in humans. This issue is illustrated by the still persistent 
failure of successful translation of effective experimental 
neuroprotective strategies into patients suffering from this 
devastating disease.
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